HUE029521T2 - Oligonukleotid kelát komplexek - Google Patents

Oligonukleotid kelát komplexek Download PDF

Info

Publication number
HUE029521T2
HUE029521T2 HUE11817618A HUE11817618A HUE029521T2 HU E029521 T2 HUE029521 T2 HU E029521T2 HU E11817618 A HUE11817618 A HU E11817618A HU E11817618 A HUE11817618 A HU E11817618A HU E029521 T2 HUE029521 T2 HU E029521T2
Authority
HU
Hungary
Prior art keywords
rep
ons
chelate
oligonucleotide
calcium
Prior art date
Application number
HUE11817618A
Other languages
English (en)
Inventor
Andrew Vaillant
Michel Bazinet
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45594559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE029521(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of HUE029521T2 publication Critical patent/HUE029521T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)

Claims (4)

  1. φ$®Μ Μ ígénypntok
    1, Gvógystókészfönéfty egy egyénben « sxubkuntn adagod oligonukleotid kövei-tetlben a szubkutár. injekció okolta mellékhatások nmpÂRésére vagy csökkentésére történd alkalmazásra. amely készítmény magában, fogki; * oligonukleotid kelét komplexet, amely keltő vagy több. ü. kationnal összekötöd, oligotiwkleotkloí tartalmim; és * gyógvszerészetüeg elfogadható hordozói ahol a komplex lega'.ahh eg% ohgonukieoúdia k^alább eg\ iosziomut komidéi rendelkezik és ahol a többért ék ü kation kétértékű fém kation.
  2. 2. Oxogsv mkés/nmére az igén)pont szeneit alkalmazás'a, ahol a R.to xagx több ohgpnukleoUd közötti kötés a í\n. z lodí észtér 4;ötés nem-hídtb oxígén-ívagy foszíotioáciö eseten ken-kmnrmm történik, es múl az ohgonokkvtiioî a " al -hh táblázatod xMa-d-pm,: í'higonakicntid Szekvencia (5'- 3') Módosítások RF.P 2(132 Ή N,:, PS RBP 2003-FI.· N!0 | PS REP 30Ü4-F1. bR PS REP 2006*VL N4Ô Ί Ä RPP2Hr?"FL N4» PS + 2' O Me RhP 2086-FL 2' O Me REP 2031-FL CahSFQ ΙΠ KO:4) i PS N ~ dégénérait szekvencia (A, O, C vagy T random beépítésével); PS foszfotioáeió minden kötésnél: 2‘ O Me « ll’-O-meíílezés minden fikáznál, I >. Gyógyszerkészítmény m F kágy t, igénypont: szerinti alMsűáxásm,: abol ikeG ulo-.i: Rntkmon kalcium
  3. 4, Gyógyszerkészítmény az 1. vagy 2. igénypont szerinti alkalmazásra, áltól a két-értlkllíiinlkation magnézium, $· Gyógyszerkészítmény az 1. vagy 2. igénypont szerinti aOrahnazésr% ábo{ a két-•Irtékü fém kation kobalt. vas(2-R mangán, réz. vagy cink. ói. Gyögy szeí'készítméoy az 1, és 3-5. igénypontok bármelyike .szegl.iiiéáífeÉiíb.átláí' re. ahol a keim komplex lege labe cm kertes s.vle okgoKnkleotul-rt unalma,
    2, Gyógy szerkészítmény az !~6, igénypontok bármelyike szerinti alkalmazásra, ahol a k$ifjkp»Rpiex legalább egy teljesen íószlóiioált oligonukleoítdot tartalmaz.
  4. 8. Oÿôgys2©ïkli^tî»éi3ÿ m bl.. igénypontok bármelyike Szerinti. alkalmazásra, ahol a kdét komplex legalább egy S’-mödosluxt-rtbítezal rendelkező oligonukicotidot tartalmaz, 9. (ïÿôgys^rkëàdMÂy az 1--8, igénypontok Mrraehikc szerinti alkdmtóte* ahol gfceját köwipiex a SI1Q ÍÖ HD; S-* 14 szekvenciák· csoportjából választóit obgonukleoildot tartalmaz,
HUE11817618A 2010-08-20 2011-08-18 Oligonukleotid kelát komplexek HUE029521T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37525710P 2010-08-20 2010-08-20

Publications (1)

Publication Number Publication Date
HUE029521T2 true HUE029521T2 (hu) 2017-03-28

Family

ID=45594559

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11817618A HUE029521T2 (hu) 2010-08-20 2011-08-18 Oligonukleotid kelát komplexek

Country Status (35)

Country Link
US (2) US8513211B2 (hu)
EP (1) EP2605794B1 (hu)
JP (1) JP5775581B2 (hu)
KR (3) KR101606495B1 (hu)
CN (2) CN103052405B (hu)
AU (1) AU2011291401B2 (hu)
BR (1) BR112013003875B1 (hu)
CA (2) CA2855690C (hu)
CL (1) CL2013000445A1 (hu)
CO (1) CO6670525A2 (hu)
CR (1) CR20130069A (hu)
CU (1) CU20130022A7 (hu)
CY (1) CY1118207T1 (hu)
DK (1) DK2605794T3 (hu)
DO (1) DOP2013000041A (hu)
EA (1) EA026660B1 (hu)
EC (1) ECSP13012449A (hu)
ES (1) ES2598556T3 (hu)
GT (1) GT201300040A (hu)
HK (2) HK1184058A1 (hu)
HR (1) HRP20161333T1 (hu)
HU (1) HUE029521T2 (hu)
IL (1) IL224237A (hu)
LT (1) LT2605794T (hu)
MX (1) MX340294B (hu)
MY (1) MY160961A (hu)
NZ (1) NZ606364A (hu)
PL (1) PL2605794T3 (hu)
PT (1) PT2605794T (hu)
RS (1) RS55245B1 (hu)
SG (1) SG187165A1 (hu)
SI (1) SI2605794T1 (hu)
SM (1) SMT201600370B (hu)
WO (1) WO2012021985A1 (hu)
ZA (1) ZA201300497B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2049664B1 (en) 2006-08-11 2011-09-14 Prosensa Technologies B.V. Single stranded oligonucleotides complementary to repetitive elements for treating DNA repeat instability associated genetic disorders
CA2723672C (en) 2007-05-11 2019-09-03 Adynxx, Inc. Gene expression and pain
ES2914775T3 (es) 2007-10-26 2022-06-16 Academisch Ziekenhuis Leiden Medios y métodos para contrarresta trastornos del músculo
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
CA3103101C (en) 2012-04-23 2023-01-17 Biomarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
CA2872901A1 (en) 2012-05-10 2013-11-14 Adynxx, Inc. Formulations for the delivery of active ingredients
EA035967B1 (ru) * 2012-05-18 2020-09-07 Репликор Инк. Композиции для лечения гепатита в, содержащие олигонуклеотидные хелатные комплексы
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
AU2013285698A1 (en) 2012-07-03 2015-02-19 Biomarin Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
BR112015003985A2 (pt) * 2012-08-30 2017-08-08 Replicor Inc métodos para tratamento de infecções de hepatite b e hepatite d
CN113750112A (zh) 2014-07-10 2021-12-07 里普利科股份有限公司 治疗b型肝炎和d型肝炎病毒感染的方法
PT3180434T (pt) 2014-08-15 2019-10-29 Adynxx Inc Chamarizes oligonucleotídicos para o tratamento da dor
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
AU2016250576C1 (en) * 2015-04-23 2021-05-06 Geron Corporation Methods of polynucleotide preparation using multivalent cation salt compositions
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
CA3117163A1 (en) * 2018-11-08 2020-05-14 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2021198958A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Nucleic acid polymers
US20220160748A1 (en) * 2020-11-20 2022-05-26 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
CA3224600A1 (en) 2021-07-09 2023-01-12 Glaxosmithkline Intellectual Property (No.3) Limited Use of oligonucleotides for individuals with renal impairment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001514873A (ja) * 1997-08-20 2001-09-18 ソーマジェニックス インコーポレイテッド 結合特性が改善されたアンチセンスおよびアンチジーン治療薬並びにそれらの使用方法
JP3667047B2 (ja) * 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
US20070105116A1 (en) 2003-09-02 2007-05-10 Japan Science And Technology Agency Metal complex type nucleic acid
WO2005026188A1 (ja) * 2003-09-08 2005-03-24 Japan Science And Technology Agency 金属錯体型核酸
CA2613101A1 (en) * 2005-07-01 2007-01-11 Bioveris Corporation Compositions and methods for detecting, amplifying, and/or isolating nucleic acids
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents

Also Published As

Publication number Publication date
CO6670525A2 (es) 2013-05-15
RS55245B1 (sr) 2017-02-28
EP2605794A1 (en) 2013-06-26
MY160961A (en) 2017-03-31
AU2011291401B2 (en) 2014-11-27
CU20130022A7 (es) 2013-04-19
GT201300040A (es) 2014-09-02
BR112013003875A2 (pt) 2018-03-13
US20130296410A1 (en) 2013-11-07
US8513211B2 (en) 2013-08-20
KR20130099067A (ko) 2013-09-05
CN103052405B (zh) 2015-11-25
EA201300259A1 (ru) 2013-12-30
ZA201300497B (en) 2013-09-25
LT2605794T (lt) 2016-10-25
IL224237A (en) 2015-09-24
DOP2013000041A (es) 2017-12-15
CR20130069A (es) 2013-09-20
HRP20161333T1 (hr) 2016-12-02
US8716259B2 (en) 2014-05-06
BR112013003875B1 (pt) 2021-10-05
CA2806616C (en) 2015-08-11
AU2011291401A1 (en) 2013-01-10
CY1118207T1 (el) 2017-06-28
ES2598556T3 (es) 2017-01-27
NZ606364A (en) 2014-12-24
CA2855690A1 (en) 2012-02-23
CN103052405A (zh) 2013-04-17
CA2806616A1 (en) 2012-02-23
HK1184058A1 (zh) 2014-01-17
WO2012021985A1 (en) 2012-02-23
CL2013000445A1 (es) 2013-11-22
JP5775581B2 (ja) 2015-09-09
JP2013536195A (ja) 2013-09-19
MX340294B (es) 2016-07-04
EP2605794A4 (en) 2014-07-02
SI2605794T1 (sl) 2017-01-31
DK2605794T3 (en) 2016-10-24
CA2855690C (en) 2015-08-25
CN103768086B (zh) 2015-10-14
SMT201600370B (it) 2016-11-10
PL2605794T3 (pl) 2017-01-31
PT2605794T (pt) 2016-10-25
EA026660B1 (ru) 2017-05-31
CN103768086A (zh) 2014-05-07
KR101606495B1 (ko) 2016-03-28
KR20150039873A (ko) 2015-04-13
HK1198123A1 (en) 2015-03-13
US20120046348A1 (en) 2012-02-23
MX2013001668A (es) 2013-07-22
EP2605794B1 (en) 2016-07-20
SG187165A1 (en) 2013-02-28
KR20150082685A (ko) 2015-07-15
ECSP13012449A (es) 2013-04-30

Similar Documents

Publication Publication Date Title
DK2605794T3 (en) Oligonukleotidchelatkomplekser
JP6294308B2 (ja) オリゴヌクレオチドキレート錯体方法
EP2155252B1 (en) Injectable polymer-lipid blend for localized drug delivery
US10434178B2 (en) Formulations for the delivery of active ingredients
AU662883B2 (en) Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases
ES2864541T3 (es) Kit mejorado para la preparación de soluciones inyectables de carmustina